Featured Research

from universities, journals, and other organizations

Protein fuels inflammation in pancreatic and breast tumors

Date:
February 23, 2011
Source:
Rockefeller University Press
Summary:
Two separate studies identify a protein that drives tumor-promoting inflammation in pancreatic and breast tumors.

Separate studies published online on February 21 in the Journal of Experimental Medicine identify a protein that drives tumor-promoting inflammation in pancreatic and breast tumors.

Inflammatory reactions come in several flavors -- Th1 and Th2, for example -- each classified according to the proteins, or cytokines, that predominate. Tumors are often infiltrated with cells that produce Th2 cytokines, which some studies suggest drive tumor growth. However, the signals responsible for initiating and maintaining Th2 inflammation in tumors are not fully understood.

Karolina Palucka and colleagues now find that human breast cancer cells release the cytokine thymic stromal lymphopoietin (TSLP) and that TSLP drives Th2 inflammation in human breast tumors. Maria Pia Protti and coworkers report that TSLP derived from fibroblasts -- cells that provide support to tumors -- fuels Th2 inflammation in human pancreatic tumors.

Although the cellular sources of TSLP differ between the two tumor types examined in these studies, the end result -- Th2 inflammation -- is the same. Future work is needed to determine if therapies targeting TSLP can help to block tumor growth.


Story Source:

The above story is based on materials provided by Rockefeller University Press. Note: Materials may be edited for content and length.


Journal References:

  1. Alexander Pedroza-Gonzalez, Kangling Xu, Te-Chia Wu, Caroline Aspord, Sasha Tindle, Florentina Marches, Michael Gallegos, Elizabeth C. Burton, Daniel Savino, Toshiyuki Hori, Yuetsu Tanaka, Sandra Zurawski, Gerard Zurawski, Laura Bover, Yong-Jun Liu, Jacques Banchereau, and A. Karolina Palucka. Thymic stromal lymphopoietin fosters human breast tumor growth by promoting type 2 inflammation. J Exp Med, February 21, 2011 DOI: 10.1084/jem.20102131
  2. Lucia De Monte, Michele Reni, Elena Tassi, Daniela Clavenna, Ilenia Papa, Helios Recalde, Marco Braga, Valerio Di Carlo, Claudio Doglioni, and Maria Pia Protti. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med., 2011 DOI: 10.1084/jem.20101876

Cite This Page:

Rockefeller University Press. "Protein fuels inflammation in pancreatic and breast tumors." ScienceDaily. ScienceDaily, 23 February 2011. <www.sciencedaily.com/releases/2011/02/110221120951.htm>.
Rockefeller University Press. (2011, February 23). Protein fuels inflammation in pancreatic and breast tumors. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2011/02/110221120951.htm
Rockefeller University Press. "Protein fuels inflammation in pancreatic and breast tumors." ScienceDaily. www.sciencedaily.com/releases/2011/02/110221120951.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins